Teva Q1 GAAP loss $0.86/share; revenue down 8%; cuts FY revenue guidance

TEVA PHARMACEUTICAL INDUSTRIES LTD

2022-Q1 EPS reported -$0.86 revenue$3,661,000,000

GAAP diluted loss per share $0.86 vs. income $0.07 in Q1 2021; non-GAAP EPS $0.55 vs. $0.63.
Revenue $3.66B, down 8% YoY (5% local currency); FY 2022 revenue guidance lowered to $15.4-$16.0B.
GAAP operating loss $713M driven by $1.1B opioid litigation settlement provisions.
COPAXONE revenue outlook cut to ~$750M from ~$850M; adjusted EBITDA and EPS guidance reaffirmed.
First generic Revlimid launched in US; AJOVY and AUSTEDO growing; opioid settlements with Florida and Rhode Island.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.